Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evofem BiosciencesEVFM -6.25% Receivables Turnover is 0.14 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Evofem Biosciences ranks worse than 60.05% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Evofem Biosciences's Revenue for the
three
months ended in Mar. 2026 was $0.90 Mil. Evofem Biosciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was $6.52 Mil.
Hence, Evofem Biosciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.14.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Evofem Biosciences Receivables Turnover Related Terms
Evofem Biosciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Evofem Biosciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVFM vs LYRA, CLSDQ, ATXI: Receivables Turnover Comparison
For the Biotechnology subindustry, Evofem Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evofem Biosciences Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences (EVFM) has a Receivables Turnover of 0.14 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Evofem Biosciences and its competitors. According to the industry distribution chart, Evofem Biosciences ranks #505 out of 841 companies in the Biotechnology industry, placing it in the top 60%.
Is Evofem Biosciences' Receivables Turnover too high?
Evofem Biosciences' current Receivables Turnover is 0.14. The Biotechnology industry median Receivables Turnover is 5.29. Evofem Biosciences' value of 0.14 is 97.4% below this industry median. Based on the distribution chart, Evofem Biosciences ranks #505 out of 841 companies in the Biotechnology industry, which is below the industry midpoint.
How does Evofem Biosciences' Receivables Turnover compare to LYRA and CLSDQ?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #505 out of 841 companies for Receivables Turnover. This places Evofem Biosciences in the lower half of its industry. The industry median Receivables Turnover is 5.29. Evofem Biosciences' value of 0.14 is 97.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evofem Biosciences's current Receivables Turnover of 0.14 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Evofem Biosciences and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evofem Biosciences's current Receivables Turnover is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 25% below its estimated fair value. The current Receivables Turnover is 0.14 and 97.4% below the Biotechnology industry median of 5.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Receivables Turnover is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVFM has been successfully added to your 
